ROS1 and neoplasm: When the 204 ROS1+ tumor samples with known PD-L1 status were analyzed, the distribution by PD-L1 expression were: 0% (n = 38), 1–49% (n = 60), and > 50% (106) (Supplementary Table 6) and were heavily impacted by NSCLC data.